← Leaderboards
Grant H Risdon
Cancure, Llc
$1,195,874
Attributed
$2,095,854
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $818.9K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,095,854 · 3
By mechanism
R44$1,499,979 · 1
R43$595,875 · 2
Top collaborators
- Jennifer D Wu2 shared
- Alan F Wahl1 shared
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsMonoclonal AntibodiesToxic EffectAntibodiesPhase I Clinical TrialsMediatingSerumProductionRecommendationColonImmunosuppressionReceptorSurfaceClinical TrialsAntigensCollaborationsClinical DevelopmentAndrogen ReceptorCheckpoint TherapyClinical ToxicologyBiophysicsBiological ProductsAntigen-Antibody ComplexCd34 Gene
Grant awards (4)
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis$295,894
R43 · FY2023 · AR · contact PI
An oral TNFα inhibitor for inflammatory bowel disease$299,981
R43 · FY2022 · DK
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer$681,039
R44 · FY2020 · CA
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer$818,940
R44 · FY2019 · CA · contact PI